Biotechnology companies developing psychedelic therapies must navigate complex Phase 1 clinical trial requirements in specialized research settings during early drug development. These trials establish safety profiles and dosing parameters for novel psychoactive compounds targeting mental health conditions. The process involves extensive preclinical research, regulatory submissions, and specialized clinical infrastructure to